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Abstract  
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Legumain is a proteolytic enzyme and playing a role in the regulation of cell proliferation 
in invasive breast cancer. Studies evaluating its role in ductal carcinoma in situ (DCIS) 
are lacking. Here, we aimed to characterise legumain protein expression in DCIS and 
evaluate its prognostic significance. Legumain was assessed immunohistochemically in a 
tissue microarray of a well characterised cohort of DCIS (n=776 pure DCIS and n=239 
DCIS associated with invasive breast cancer (DCIS-mixed)). Legumain immunoreactivity 
was scored in tumor cells and surrounding stroma and related to clinicopathological 
parameters and patient outcome. High legumain expression was observed in 23% of 
pure DCIS and was associated with features of high risk DCIS including higher nuclear 
grade, comedo necrosis, hormone receptor negativity, HER2 positivity and higher 
proliferation index. Legumain expression was higher in DCIS associated with invasive 
breast cancer than in pure DCIS (p<0.0001). In the DCIS-mixed cohort, the invasive 
component showed higher legumain expression than the DCIS component (p<0.0001). 
Legumain was an independent predictor of shorter local recurrence free interval for all 
recurrences (p=0.0003) and for invasive recurrences (p=0.002). When incorporated with 
other risk factors, legumain provided better patient risk stratification. High legumain 
expression is associated with poor prognosis in DCIS and could be a potential marker to 
predict DCIS progression to invasive disease.  
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INTRODUCTION 
The key strategies for breast ductal carcinoma in situ (DCIS) management are to 
prevent its progression into invasive disease and to avoid disease recurrence, particularly 
invasive breast carcinoma which accounts for half of the recurrences. Identifying high 
risk DCIS that have potential to invade is an excellent approach towards patient risk 
assessment and stratification for individualized management (1). However, since the 
current clinicopathological parameters are inadequate to define DCIS risk precisely, 
identification of novel prognostic markers is necessary (2, 3). Furthermore, the newly 
described genetic signatures such as Oncotype DX DCIS for prediction of recurrence 
show controversial results and need further validation (4-9). Of note, genes included in 
Oncotype DX signature are mainly related to cellular proliferation and metabolism as 
subsequent indicators of invasion rather than invasive potential (6). In addition, 
currently available risk indices such as Van Nuys Prognostic Index and nomograms rely 
mainly on clinicopathological parameters and to lesser extent on markers related to the 
tumor cells with little consideration for the surrounding microenvironment (7, 10-12). 
With the emerging role of tumor  microenvironment and the related proteins in the 
disease behaviour (13), identification of more robust genetic signatures incorporating the 
crosstalk between tumor  epithelial cells and surrounding microenvironment might 
provide a better approach for DCIS risk assessment and hence better management. 
Basement membrane degradation and stromal remodelling are fundamental steps in 
progression from DCIS into invasive disease. Although the key role of matrix 
metalloproteinases in stromal breakdown is undeniable, explanation of DCIS progression 
into invasive disease depending solely on them is insufficient. Studies that targeted 
blocking metalloproteinases action in order to prevent disease progression reported non-
promising results (14, 15). Taken together, identification of novel markers that play a 
role in DCIS invasiveness might help in better understanding of the disease biology and 
risk stratification.          
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Legumain (LGMN) is a cysteine endopeptidase belonging to the asparaginyl 
endopeptidase family encoded by the legumain gene (16, 17). Legumain activates 
zymogen gelatinase A by cleavage of pro-gelatinase A, which is an important mediator of 
extracellular matrix degradation, thereby helping the tumor to invade and metastasize 
(18-20). It also activates other proteases that are key in regulating angiogenesis, growth 
and other related functions in tumor s (21). legumain is expressed at elevated levels in 
invasive breast cancer (16, 22), colorectal (23), prostate (24) and gastric carcinomas 
(17) and is related to poor prognosis (21). Moreover, legumain is differentially expressed 
between normal breast tissue and invasive breast cancer (16), however the role of 
legumain in DCIS has yet to be established. In this study, we aim to assess the pattern 
of legumain expression and its prognostic significance in a large well-annotated DCIS 
cohort.   
MATERIAL AND METHODS 
Study Cohort  
A well characterised annotated cohort of DCIS including pure DCIS (n=776) and DCIS 
mixed with invasive breast cancer (DCIS-Mixed) (n=239) diagnosed between 1990 to 
2012 at Nottingham City Hospital, Nottingham, United Kingdom was used as previously 
described (25). Patients’ demographic data, histopathological parameters, management 
including post-operative radiotherapy and development of local recurrence were collected 
(Supplementary Table 1). Local recurrence free interval was defined as the time (in 
months) between 6 months after the first DCIS surgery and occurrence of ipsilateral 
local recurrence (either as DCIS or invasive breast cancer). Cases undergoing re-
operation within the first 6 months due to close surgical margins or presence of residual 
disease were not counted as recurrence. Patients who developed contralateral disease 
following DCIS diagnosis were censored at the time of development of the contralateral 
cancer. Within a median follow up period of 103 months (range 6-240), 83 cases (11%) 
developed a recurrence in the pure DCIS cohort compromising 30 DCIS (36%) and 53 
invasive cancer with or without DCIS (64%). Six recurrence events were developed after 
 4
mastectomy and 11 events after management with breast conserving surgery followed 
by adjuvant radiotherapy while the majority of the recurrences (n=66) occurred after 
breast conserving surgery alone.  
Additionally, data on different molecular classes and tumor infiltrating lymphocytes 
density were available for the cohort (25, 26). To avoid selection bias, the DCIS-mixed 
cohort was selected with clinicopathological features comparable to the pure cohort 
regarding age at diagnosis, DCIS nuclear grade, and the presence of comedo necrosis. 
Immunohistochemistry 
Tissue microarrays were prepared from both cohorts. The TMA was constructed using a 
TMA GRAND MASTER 2.4-UG-EN MACHINE, using 1 mm punch sets. Cases with 
heterogeneous DCIS morphological patterns or grade were sampled from all 
representative areas. In addition, whole tissue sections from 20 cases compromising 10 
pure DCIS and 10 DCIS-mixed cases were assessed to evaluate the pattern of legumain 
expression in malignant breast tissue and adjacent stroma and normal tissue. 
Primary antibody specificity for rabbit polyclonal legumain antibody [ab125286, Abcam, 
UK] was validated using Western Blot on whole cell lysates of MCF7 and SKBR3 human 
breast cancer cell lines (obtained from the American Type Culture Collection; Rockville, 
MD, USA) as previously described (27-29). Legumain antibody was used at a dilution of 
1:500, which showed a single specific band at the predicted size of 56 KDa.  
Expression of legumain protein in DCIS was assessed by immunohistochemistry using 
the Novocastra Novolink TM Polymer Detection Systems kit (Code: RE7280-K, Leica, 
Biosystems, UK). Tissue microarray and full-face sections (4 µm) were stained with 
rabbit polyclonal legumain (dilution 1:150), incubated for 24 hours. Normal kidney tissue 
was used as a positive control while a negative control was carried out by omitting the 
primary antibody. 
Scoring of legumain expression  
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Percentage of cells showing cytoplasmic granular/vesicular staining (16) was estimated 
in tumor epithelial cells and the surrounding stromal fibroblasts, separately. Cores 
containing <15% either tumor epithelial cells and/or stroma were excluded from the 
scoring. All scored cores showed representative areas of specialised stroma (within two 
high power fields) (30) surrounding the malignant ducts. In addition, the few cores 
included malignant epithelial cells only were excluded as it was difficult to differentiate 
between in situ or invasive process and the origin of these tumour cells. This method 
aimed to improve the reliability of the study and the cases excluded were random. Cases 
with multiple cores were scored and the average score was used for the analysis. For 
mixed cohort, each component, DCIS and invasive, was scored separately for the tumor 
epithelial cells and surrounding stroma. The cases were scored by two pathologists (MST 
and IMM) using a multiheaded microscope, considering the percentage of positive 
staining of any intensity. For dichotomization of protein expression, cut-off points for 
either malignant epithelial cells or stromal expression of legumain were defined 
according to the conducted results from X-tile bioinformatics software (Yale University, 
version 3.6.1) (31) based on local recurrence free interval in the pure DCIS cohort. High 
legumain expression within tumor epithelial cells was considered when more than 65% 
of tumor cells showed staining, while expression in more than 10% of the surrounding 
fibroblasts was considered high expression.  
Analysis of legumain mRNA expression in breast cancer: 
To emphasise the prognostic role of legumain in breast cancer and given the lack of data 
on the transcriptomic profiles of DCIS, legumain normalised mRNA expression was 
evaluated as a potential prognostic marker in the Molecular Taxonomy of Breast Cancer 
International Consortium (METABRIC) cohort dataset (32), which comprises a large 
(n=1980) cohort of invasive breast cancer with comprehensive molecular 
characterisation. Moreover, to validate the prognostic significant of legumain in breast 
cancer, analysis using the Breast Cancer Gene-Expression Miner v4.1 (bc-GenExMiner 
v4.1) database was carried out. 
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Statistical analysis 
Statistical analyses were performed using SPSS v21 (Chicago, IL, USA) for Windows. 
Student’s t test and analysis of variance (ANOVA) were used to correlate between 
legumain mRNA level as a continuous variable and other clinicopathological parameters 
in METABRIC data. Association with legumain mRNA expression and breast cancer 
specific survival was performed after dichotomisation of expression into high and low 
groups based on the median value.  
Spearman’s Rho test was used to correlate between legumain expression with the tumor 
epithelial and stromal cells. Association between legumain expression and 
clinicopathological parameters in pure DCIS was performed using Chi-square, Mann 
Whitney and Kruskal-Wallis tests. Wilcoxon signed rank test was used to compare the 
expression of legumain between DCIS component and invasive component within the 
DCIS-mixed cases. Univariate survival analysis against local recurrence free interval was 
carried out using log rank test and Kaplan Meier curves. Cox regression model was used 
for multivariate analysis of legumain expression for all recurrences (either DCIS or 
invasive breast cancer) and invasive recurrences. For all tests, a two-tailed p-value of 
less than 0.05 was considered as statistically significant. 
This work obtained ethics approval by the North West – Greater Manchester Central 
Research Ethics Committee under the title; Nottingham Health Science Biobank (NHSB), 
reference number 15/NW/0685. 
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RESULTS 
Pattern of legumain expression 
The evaluation of full-face tissue sections demonstrated representative distribution of 
legumain expression either the tumor epithelial cells or the surrounding specialised 
stroma throughout the whole section, indicating representability of tissue microarrays to 
assess legumain expression in our cohort. Adjacent normal breast terminal duct-lobular 
units showed negative or very faint cytoplasmic staining of legumain. Occasional 
inflammatory and stromal cells were also stained in few cores. When present, legumain 
was expressed in the cytoplasm of the epithelial tumor cells and surrounding fibroblasts 
(Figure 1).  
After unbiased exclusion of uninformative cores (lost cores, folded tissue during 
processing and staining of cores containing <15% tumor cells and/or stroma), the final 
number of cases suitable for scoring was 464 pure DCIS and 191 DCIS-mixed. Legumain 
expression showed a unimodal distribution. The median percentage of positive tumor 
epithelial cells was 25% in pure DCIS, 30% in the DCIS component of mixed cases, and 
60% in invasive component of the latter (all showed a range between 0-100%). For 
stromal expression, the median percentage of positive stromal cells was 5% in pure 
DCIS (range 0-80%), 70% in the DCIS component of mixed cases (range 0-80%) and 
90% in the invasive component of the latter (range 0-90%). Within the pure DCIS 
cohort, high legumain expression was observed in 23% and 44% in tumor epithelial and 
surrounding stromal cells; respectively. There was a positive linear correlation between 
expression of legumain within the epithelial cells and surrounding fibroblasts (r=0.408, 
p<0.0001, Spearman’s correlation).  
The proportion of cases with high legumain was greater in DCIS-mixed than pure DCIS, 
both within the tumor epithelial cells (23% of pure DCIS cases vs. 36% of DCIS mixed 
with invasive breast cancer, χ2=11.7, p=0.001) and stromal cells (44% for pure DCIS vs. 
86% of DCIS mixed with invasion, χ2=95.5, p<0.0001). Similar results were observed 
when the data was analysed using a continuous scale (p=0.049 and p<0.0001, for 
tumor epithelial cells and stromal cells, respectively). Moreover, there was a statistically 
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significant difference between legumain expression within the tumor epithelial cells of 
the DCIS component and invasive component of DCIS-mixed cases (p<0.0001). 
Similarly, legumain staining was more frequent in the stromal fibroblasts surrounding the 
invasive component than those surrounding the DCIS component (p<0.0001) (Figure 2). 
Significance of legumain expression in pure DCIS 
High expression of legumain within the malignant epithelial cells and/or surrounding 
stromal fibroblasts in the pure DCIS was associated with various clinicopathological 
parameters characteristic of poor prognosis, including high nuclear grade, presence of 
comedo necrosis, hormonal receptor negativity, HER2 positivity, high proliferative index, 
and dense tumor infiltrating lymphocytes (Table 1). Analysis of continuous data of 
legumain expression scores showed similar results (Supplementary Table 2).  
To validate the prognostic value of legumain in invasive breast cancer, the METABRIC 
cohort (32) was used to assess the levels of legumain mRNA and correlate its expression 
with the clinicopathological variables and outcome. Higher legumain mRNA level was 
associated with high tumor grade (p=0.03), lymph node metastasis (p=0.04), estrogen 
receptor negativity (p=0.001), HER2 positivity (p=0.006) in addition to shorter breast 
cancer specific survival (HR=1.3, 95% CI=1.1-1.5, p=0.007) (Supplementary Tables 3, 
and Supplementary Figure 1).  Analysis using the Breast Cancer Gene-Expression Miner 
v4.1 (bc-GenExMiner v4.1) database showed that high legumain mRNA was associated 
with higher metastatic relapse and/or death (HR=1.3, 95% CI=1.1-1.5, p=0.0001).  
Outcome analysis in pure DCIS cohort  
High legumain expression within tumor epithelial cells was associated with shorter local 
recurrence free interval (all recurrences either as in situ or invasive disease) in pure 
DCIS (HR=2.7, 95% CI=1.6-4.8; p=0.0002, Figure 3). Association with shorter local 
recurrence free interval was observed in patients treated with breast conserving surgery 
without adjuvant radiotherapy (HR=2.6, 95% CI=1.4-4.4; p=0.002, Figure 3) however; 
the significant association with poor outcome was not maintained in patients treated with 
either mastectomy (HR=0.9, 95% CI=0.1-8.8; p=0.9) or breast conserving surgery 
followed by adjuvant radiotherapy (HR=2.4, 95% CI=0.8-10.4; p=0.08). Interestingly, 
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there was an association between high legumain expression and ipsilateral local 
recurrence as invasive disease (HR=3.1, 95% CI=1.5-6.5; p=0.001, Figure 3) 
particularly in patients treated with breast conserving surgery without post-operative 
adjuvant radiotherapy (HR=3.3, 95% CI=1.5-7.3; p=0.004). Supplementary Figure 2 
shows forest plots illustrating the hazard ratio for disease recurrence of the different 
clinicopathological parameters in patients treated with breast conserving surgery based 
on univariate survival analysis. Stromal expression of legumain did not show any 
significant association with tumor recurrence.   
Multivariate survival analysis showed that high expression of legumain in tumor  cells 
was a poor prognostic factor for tumor  recurrence in patients treated with breast 
conserving surgery independent of known other determinants of high risk DCIS including 
age at diagnosis, DCIS size, presentation, nuclear grade, comedo necrosis, margin 
status, molecular classes, and radiotherapy either for all recurrences (HR=3.5, 95% 
CI=1.8-4.9; p=0.0003) or when the analysis confined to invasive recurrences (HR=3.4, 
95% CI=1.8-8.3; p=0.002) (Table 2 and Figure 4). 
Interestingly, when legumain expression in tumor cells was incorporated with the other 
determinants of DCIS risk described by Van Nuys Prognostic Index (12), it provided 
better stratification for local recurrence risk, whereby high expression of legumain was 
associated with worse outcome in all risk groups when compared to similar groups with 
low legumain expression (Figure 5).  
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DISCUSSION 
The underlying mechanisms promoting the transition from DCIS to invasive disease 
remain unclear and there is a demand to gain a better understanding. Several studies 
and risk assessment models are available; however, none is adequate for patients’ risk 
stratification and hence a considerable percentage of patients with DCIS are either over- 
or under-treated. Furthermore, the biological and clinical heterogeneity of DCIS makes 
risk stratification quite challenging. An explanation of disease progression based 
exclusively on intrinsic tumor cell factors is insufficient, as there is a group of low grade 
DCIS with indolent appearance and low proliferation index that yet carries progression 
potential to invasive breast cancer (33). Studying the role of the DCIS microenvironment 
and the interaction between its various components and understanding how this 
influences disease behaviour could resolve the DCIS dilemma and provide a more 
adequate risk stratification model for personalised management (34-37). As invasion 
through the outer myoepithelial later and basement membrane degradation is a key step 
in DCIS progression to invasive cancer, studying potential markers that drive this process 
and their prognostic value is a convincing approach to refine DCIS risk. 
The lysosomal cysteine protease legumain is a proteolytic enzyme and plays role in 
autoimmunity and cancer (21, 38, 39). Overexpression of legumain is linked with poor 
prognosis in different tumor s including invasive breast cancer (17, 22-24, 40, 41). Its 
action depends mainly on increasing the invasive and metastatic potential of the tumor 
via its proteolytic properties and stromal degradation (38). Comparing legumain 
expression between normal, borderline and invasive ovarian tissues reveals that it has a 
role not only in tumor migration and invasion but also in tumor development (40). 
However, similar studies are lacking in breast cancer to assess the role of legumain in 
DCIS. It was reported that legumain is differentially expressed between normal breast 
tissue and invasive breast cancer (16, 21, 39). Furthermore, using the METABRIC cohort 
for robust molecular data in a large number of invasive breast cancer, we have shown an 
association between aggressive behaviour of invasive breast cancer and higher levels of 
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legumain mRNA. These observations support our hypothesis that legumain is a 
promising candidate marker that requires additional studies to decipher its role in DCIS 
behaviour.  
Here we explored the expression of legumain in a large well characterised cohort of DCIS 
and scored the protein expression in tumor cells and surrounding stromal fibroblasts. 
Interestingly, high legumain expression was associated with other features of high risk 
DCIS. These findings support the role of legumain in DCIS progression. Supporting this, 
our results showed that legumain expression is higher in DCIS co-existing with invasive 
carcinoma than pure DCIS, and much higher in the invasive component either within the 
tumor cells or in the surrounding stromal fibroblasts.         
The poor prognostic value of legumain was shown with a shorter recurrence free interval 
in patients with high levels of legumain expression independently from other 
clinicopathological factors. These findings were consistent for all recurrent events, either 
DCIS or invasive breast cancer or when the analysis was confined to invasive 
recurrences only, which provides more evidence that legumain plays a key role in DCIS 
progression to invasive disease. Our study shows that expression of legumain in tumor 
epithelial cells, but not stromal cells, is associated with recurrence; a finding that might 
reflect the potential epithelial cell-intrinsic role of early stage tumor s in extracellular 
matrix degradation that facilitates tumor progression and the dual role of tumor  and 
stromal cells in progression and aggressiveness of advanced tumor s. The latter 
interaction is supported by the dramatic increase of legumain expression in stromal cells 
surrounding the invasive component compared to those surrounding the DCIS 
component in mixed cases or those surrounding pure DCIS. However, further functional 
studies are highly recommended to understand the underlying mechanisms and 
functions of legumain expression in carcinogenesis and tumor progression either from 
the tumor cells or the surrounding stroma. 
Incorporation of legumain with the other clinicopathological factors provided a better 
identification of different risk groups. These findings indicate that legumain is a 
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promising marker for better definition of high risk DCIS as well as for the identification of 
patients with lower risk where radiotherapy could be omitted. 
Thus far, little is known about the biological processes which involve legumain in cancer 
progression. However, a correlation was observed between tumor invasion and 
metastasis and the presence of cysteine endopeptidases, such as cathepsins B and L 
(42). Protease zymogen cathepsins B and L may also be activated by legumain-mediated 
hydrolysis of asparaginyl bonds. Legumain acts as an asparaginyl endopeptidase in 
regulation of extracellular matrix remodelling through the activation of zymogen 
progelatinase A, which is an important mediator of extracellular matrix degradation, or 
the degradation of fibronectin, which is a main component of the extracellular matrix 
(43, 44). Animal tumor models generated with cells overexpressing legumain 
demonstrated an in vivo behaviour that is vigorous with more invasive growth and 
metastasis (39). This phenotype is proposed to result from the proteolytic function of 
legumain to activate other protease zymogens. The inhibitory effect of cystatins on 
tumor cells is consistent with the involvement of legumain, and perhaps other cysteine 
proteases, in tumor invasion and metastasis. Whether the tumor suppressing effect is 
mediated through inhibition of legumain catalytic activity or other cysteine proteases is 
presently unknown (43).   
Legumain is present intracellularly in a pro-active form (38, 39) and one of the activating 
mechanisms is low pH. Interestingly, our findings showed that legumain is associated 
with presence of comedo type necrosis, which is consistent with low pH and supports our 
findings. Legumain is usually overexpressed in cells adjacent to necrosis (39), which was 
observed in our study as well where central cells facing the comedo necrosis showed 
higher legumain expression than the peripheral cells within the ducts.   
The role of legumain in tumor aggressiveness is not related solely to its proteolytic 
activity but also to its proliferation activation mechanisms. This may be related to 
decreased apoptotic activity of cells and increased calcium influx into cells (21, 45). 
Supporting this possibility, our study showed that legumain was expressed in highly 
 13
proliferative DCIS, which may further augment the adverse action of legumain in the 
context of disease outcome.  
The role of legumain in autoimmune disease and inflammatory process is undeniable 
(38). Legumain functions in antigen presentation to inflammatory cells may be a cause 
for such phenomenon. Overexpression of legumain in tumor associated macrophages 
and endothelial cells of the surrounding tissues has been reported (41). Accordingly, the 
link between legumain and dense inflammatory cells infiltrates is warranted to be 
investigated. We previously reported that dense tumor infiltrating lymphocytes have poor 
prognostic significance in DCIS, a reverse phenomenon to the invasive disease for which 
the underlying mechanisms are unclear (26). We saw a striking association of high 
stromal legumain and a dense lymphocytic infiltrate in pure DCIS (Table 1) that may be 
associated with an inflammatory function for legumain. Taken together, legumain may 
interact with the inflammatory cascade and affect DCIS behaviour.  
Conclusion  
Extracellular matrix degradation is an essential step for DCIS progression to invasive 
disease. Legumain might have a potential role in DCIS aggressiveness through its 
proteolytic activity and regulatory mechanism in cellular proliferation. Additional 
functional studies to decipher the role of legumain and its mechanism of action in DCIS 
behaviour are warranted. Legumain may also be a valuable prognostic indicator 
especially for invasive recurrence.  
Limitations of the study 
This study has been carried out on TMA sections, which might underestimate the role of 
tumour heterogeneity. However, all cases in our cohort were histologically reviewed 
before TMA construction and used multiple cores for cases with heterogeneous grades or 
morphological patterns. Moreover, our cohort did not include any patients treated with 
endocrine therapy.  
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Table 1: Correlation between legumain expression with different clinicopathological 
parameters in the pure DCIS cohort. 
Significant p values are in bold  
DCIS; ductal carcinoma in situ, HER2; Human epidermal growth factor receptor 2, n; number  
*Including the cases in both cohorts; i.e. pure DCIS cohort (n=464) + DCIS-mixed cohort (n=191).   
Clinicopathological  
Parameters
Legumain expression in 
tumor epithelial cells
χ2 
(p-value)
Legumain expression in 
stromal fibroblasts
χ2 
(p-value)Low 
(N=359) 
N. (%)
High 
(N=105) 
N. (%)
Low  
(N=259) 
N. (%)
High 
(N=205) 
N. (%)
Age (years) 
   ≤50  
   >50 
88 (25) 
271 (75)
27 (24) 
78 (76)
0.1 
(0.802) 62 (24) 197 (76)
53 (26) 
152 (74)
0.3 
(0.635)
Presentation  
   Screening 
   Symptomatic
177 (49) 
182 (51)
48 (46) 
57 (54)
0.4 
(0.517)
134 (51) 
125 (49)
91 (44) 
114 (56)
2.5 
(0.116)
DCIS Size (mm) 
   <16 
   16-40  
   >40
112 (31) 
148 (41) 
98 (28)
22 (21) 
45 (43) 
37 (36) 
4.8 
(0.092)
77 (30) 
107 (41) 
75 (29)
57 (28) 
86 (42) 
60 (30)
0.2 
(0.927)
Nuclear Grade 
   Low 
   Moderate 
   High
51 (14) 
113 (32) 
195 (54)
8 (8) 
15 (14) 
82 (78)
19.2 
(<0.0001)
39 (15) 
84 (32) 
136 (53)
20 (10) 
44 (21) 
141 (69)
12.6 
(0.002)
Comedo necrosis  
   Yes 
   No
226 (63) 
133 (37)
80 (76) 
25 (23)
6.3 
(0.012)
160 (62) 
99 (38) 
59 (30) 
146 (70)
4.5 
(0.033)
Estrogen receptor   
   Negative 
   Positive
62 (19) 
266 (81)
54 (54) 
47 (46) 46.8 (<0.0001)
42 (18) 
195 (82)
74 (39) 
118 (62)
23.3 
(<0.000
1)
Progesterone receptor 
   Negative 
   Positive
114 (34) 
217 (66)
67 (66) 
35 (34) 31.3 (<0.0001)
76 (32) 
165 (68)
105 (55) 
87 (45)
23.5 
(<0.000
1)
HER2 status  
   Negative 
   Positive
256 (79) 
68 (21)
60 (63) 
35 (37)
9.9 
(0.002)
190 (80) 
47 (20)
126 (69) 
56 (31)
6.6 
(0.010)
P r o l i f e r a t i o n i n d e x 
(Ki-67) 
   High 
   Low
59 (20) 
240 (80)
36 (37) 
62 (63) 11.7 (0.001)
31 (33) 
184 (67)
64 (61) 
118 (40)
23.3 
(<0.000
1)
Molecular classes 
   Luminal A 
   Luminal B 
   HER2 Enriched  
   Triple negative
160 (58) 
61 (22) 
25 (9) 
29 (11)
22 (24) 
18 (20) 
22 (25) 
28 (31)
46.4 
(<0.0001)
127 (63) 
35 (18) 
19 (10) 
18 (9)
55 (33) 
44 (26) 
28 (17) 
39 (24)
36.3 
(<0.000
1)
T u m o u r i n f i l t r a t i n g 
lymphocytes   
   Dense 
   Sparse 
123 (44) 
159 (56)
55 (63) 
33 (37)
9.6 
(0.002)
72 (36) 
130 (64)
106 (63) 
62 (37)
27.7 
(<0.000
1)
DCIS Type* 
   Pure DCIS 
   DCIS with invasive breast 
cancer
359 (75) 
123 (25)
105 (61) 
68 (39) 11.7 (0.001)
259 (91) 
27 (9)
205 (56) 
164 (44)
95.6 
(<0.000
1)
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Table 2: Multivariate survival analysis (Cox regression model) of variables predicting 
outcome in terms of ipsilateral local recurrence in patients treated by breast conserving 
surgery in pure DCIS cohort 
A) All recurrences  
B) Invasive recurrence  
Significant p values are in bold                     
Parameters  Hazard ratio 
(HR)
95% confidence interval (CI)   
p-value
Lower Upper
High legumain expression 3.5 1.8 4.9 0.0003
Patient Age 1.4 1.2 2.6 0.019
DCIS presentation 1.8 0.8 3.8 0.103
DCIS size 0.8 0.5 1.3 0.297
DCIS nuclear Grade 1.5 0.9 2.6 0.148
Comedo necrosis 0.7 0.3 1.4 0.268
Molecular classes 0.8 0.6 1.2 0.260
Radiotherapy 0.3 0.1 0.9 0.045
Margin status 0.8 0.4 1.3 0.752
Parameters  Hazard ratio 
(HR)
95% confidence interval (CI)   
p-value
Lower Upper
High legumain expression 3.4 1.8 8.3 0.002
Patient Age 1.5 0.7 2.3 0.129
DCIS presentation 1.4 0.5 3.6 0.511
DCIS size 1.2 0.6 2.4 0.688
DCIS nuclear Grade 1.4 0.7 2.9 0.349
Comedo necrosis 1.1 0.4 2.8 0.912
Molecular classes 0.5 0.3 0.9 0.027
Radiotherapy 0.2 0.1 0.9 0.040
Margin status 0.9 0.4 1.9 0.813
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DCIS; ductal carcinoma in situ 
Supplementary Table 1: Characterization of pure DCIS cohort (n=464) 
Clinicopathological  
Parameters
No. of cases (%)
Age (years) 
   ≤50  
   >50 
115 (25) 
349 (75)
Presentation  
   Screening 
   Symptomatic
225 (49) 
239 (51)
DCIS Size (mm) 
   <16 
   16-40  
   >40
134 (29) 
193 (42) 
135 (29)
Nuclear Grade 
   Low 
   Moderate 
   High
59 (12) 
128 (28) 
277 (60)
Comedo necrosis*  
   Yes 
   No
306 (66) 
158 (34)
Estrogen receptor   
   Negative 
   Positive
116 (27) 
313 (73)
Progesterone receptor 
   Negative 
   Positive
181 (42) 
252 (58)
HER2 status  
   Negative 
   Positive
316 (75) 
103 (25)
Proliferation index (Ki-67) 
   High (>14%) 
   Low (≤14%)
95 (24) 
302 (76)
Molecular classes 
   Luminal A 
   Luminal B 
   HER2 Enriched  
   Triple negative
182 (50) 
79 (22) 
47 (13) 
57 (15)
Tumour infiltrating lymphocytes   
   Dense 
   Sparse 
178 (48) 
192 (52)
Treatment  
   Mastectomy 
   Breast conserving surgery 
   Breast conserving surgery+ adjuvant Radiotherapy 
259 (56) 
137 (30) 
68 (14)
Margin status** 
   Positive (tumour on ink) 
   <2mm free margin  
   ≥2mm free margin 
5 (2) 
6 (2) 
194 (96)
 21
*Comedo necrosis defined definite central necrosis within the DCIS ducts that have been 
identified as necrosis with nuclear debris (we did not use % as this was subjective). 
Cases showing apoptotic bodies or single cell necrosis were not considered as comedo 
necrosis. 
**Based on new guidelines by the American Society of Clinical Oncology and the Society 
of Surgical Oncology 2016. Data shown here is for cases treated with BCS (n=205) 
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Supplementary Table 2: Correlation between legumain expression and different 
clinicopathological parameters in the pure DCIS cohort using continuous data.  
Significant p values are in bold  
DCIS; ductal carcinoma in situ, HER2; Human epidermal growth factor receptor 2 
Clinicopathological  
Parameters
Number of 
cases
Legumain expression in 
tumor epithelial cells 
Legumain expression in 
stromal fibroblasts
Mean Rank p-value Mean Rank p-value
Age (years) 
   ≤50  
   >50 
115 
349
225.1 
234.9
0.488 243.4 
228.9
0.276
Presentation  
   Screening 
   Symptomatic
225 
239
228.8 
235.9
0.563 221.7 
242.6 0.070
DCIS Size (mm) 
   <16 
   16-40 
   >40
134 
193 
135
211.7 
231.6 
250.9
0.054 224.9 231.8 
237.5
0.701
Nuclear Grade 
   Low 
   Moderate 
   High
59 
128 
277
198.9 
201.1 
254.1
<0.0001 207.1 208.5 
248.9
0.002
Comedo necrosis  
   Yes 
   No
306 
158
247.4 
203.5
0.001 242.5 
213.1
0.016
Estrogen receptor   
   Negative 
   Positive
116 
313
277.5 
191.9
<0.0001 262.9 
197.3
<0.0001
Progesterone Receptor 
   Negative 
   Positive
181 
252
259.9 
186.2
<0.0001 250.7 
192.8
<0.0001
HER2 status 
   Negative 
   Positive
316 
103
195.9 
253.1
<0.0001 200.9 
238.0
0.003
Proliferation index (Ki-67) 
   High 
   Low
95 
302
245.3 
184.4
<0.0001 244.2 
184.7
<0.0001
Molecular classes 
   Luminal A 
   Luminal B 
   HER2 Enriched  
   Triple negative
182 
79 
47 
57
146.3 
195.4 
237.4 
238.2
<0.0001
151.9 
201.6 
214.3 
230.6
<0.0001
T u m o u r i n f i l t r a t i n g 
lymphocytes    
   Dense 
   Sparse
178 
192
207.5 
165.1 <0.0001
216.3 
156.9 <0.0001
DCIS Type 
   Pure DCIS 
   DCIS with invasive breast cancer
464 
191
319.2 
349.4
0.049 283.2 
436.8
<0.0001
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Supplementary Table 3: Correlation between legumain mRNA level and the 
clinicopathological parameters in the METABRIC series of invasive breast cancers 
(n=1980). 
Significant p values are in bold  
METABRIC; Molecular Taxonomy of Breast Cancer International Consortium 
Clinicopathological parameters Number of cases Mean Legumain mRNA level p-value
Patient Age (years) 
   <50  
   ≥50 
383 
1556
8.7 
8.6
0.746
Tumour Size (mm) 
   ≤20 
   >20
622 
1331
8.7 
8.5
0.443
Histologic Grade 
   1 
   2  
   3
170 
770 
952
8.2 
8.2 
8.3
0.034
Lymph node metastasis  
   Negative 
   Positive
1035 
938
8.5 
8.6
0.040
Estrogen Receptor Status 
   Positive 
   Negative
1506 
474
8.4 
8.9
0.001
HER2 Status 
   Negative 
   Positive
1733 
247
8.5 
8.8
0.006
PAM50 molecular classes 
   Luminal A 
   Luminal B 
   Basal-like 
   HER2 enriched 
   Normal like
718 
488 
329 
240 
199
8.4 
8.5 
9.0 
8.7 
8.9
<0.0001
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Figure 1: A) Normal breast ductolobular unit (x20) shows negative staining of 
legumain; B) Negative legumain expression (x20) in a pure DCIS case; C) strong 
expression of legumain in tumor cells and surrounding fibroblasts (x20) in a pure DCIS 
case (Inset: high power view showing the granular pattern of legumain expression). D) 
High expression of legumain in the fibroblasts surrounding DCIS case (x40). E) 
Expression of legumain in a mixed case (x40) showing strong staining in invasive 
component either within the tumor cells or surrounding stromal fibroblasts. 
!
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Figure 2: Bar chart showing differences of legumain expression between pure DCIS and 
DCIS-mixed both in tumor cells (black bars) and surrounding stroma (grey bars).   
P-value from ANOVA, Error bars represent +2 standard deviation.  
%
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Figure 3: Kaplan Meier curves show that high expression of legumain within the tumor 
epithelial cells is associated with shorter ipsilateral local recurrence free interval in the 
whole series (A), and in breast conserving surgery (BCS) without adjuvant radiotherapy 
(B). High expression also showed an association with shorter local recurrence free 
interval as invasive disease in the whole series (C) and in patients treated with breast 
conserving surgery without adjuvant radiotherapy (D). 
!
!
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Figure 4: Forest plots showing the hazard ratio of the different clinicopathological 
parameters and ipsilateral tumor recurrence for patients treated with breast conserving 
surgery in pure DCIS cohort based on the multivariate analysis results for; A) all 
recurrences whether DCIS or invasive breast cancer and B) for invasive recurrences only.  
%
%
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Figure 5: Kaplan Meier curves show the association between DCIS risk and local 
recurrence free interval in patients treated with breast conserving surgery based on Van 
Nuys Prognostic Index alone (A), and when legumain was incorporated with the Van 
Nuys Prognostic Index (B).   
!
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Supplementary Figure 1: Association between legumain mRNA level and outcome in 
terms of breast cancer specific survival (BCSS) in the METABRIC series. The cohort was 
split into high and low mRNA expression based on the median (8.59).  
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Supplementary Figure 2: Forest plots showing the univariate analysis results of 
association between different clinicopathological parameters and ipsilateral tumor 
recurrence for patients treated with breast conserving surgery in pure DCIS cohort; A) 
all recurrences whether DCIS or invasive and B) for invasive recurrences only. High 
expression of legumain in tumor epithelial cells is associated with higher recurrence risk 
in both groups.
%
%
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